Beyond Data: The Value of eCTD Regulatory Operations

While new drug development companies tend to focus on the validity and safety results of clinical trial data, the process of actually submitting this data to regulatory agencies requires a completely different level of expertise. Simply collecting completed research reports is not enough to create an Electronic Common Technical Document (eCTD) that meets regulatory standards. Regulatory Operations (RegOps) can be seen as a specialized field that designs the interconnected structure of complex documents and meticulously reviews hyperlinks and navigation. Therefore, the generation of data and the planning of regulatory operations must proceed in parallel to minimize the risk of approval delays.

Strategic Need for Early Integration of Regulatory Operations

If the publishing solution is activated late in the document preparation process, it will inevitably lead to serious scheduling bottlenecks. Premier Research emphasizes that defining the architecture from the early stages of document preparation and evaluating the reusability of existing data can reduce unexpected compliance risks. In particular, for multinational clinical companies preparing for simultaneous submissions to the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), early intervention is essential to comply with the different formats and metadata standards of each region. The key to Submission Readiness is not when the research is completed, but when a continuous feedback loop with the regulatory team is formed while the research is in progress.

The Effect of Introducing a Rolling Submission Method

In the new drug approval application process, a rolling submission strategy, which processes completed documents sequentially without waiting for all documents to be completed, is effective. To this end, a pipeline-style collaboration is required in which the regulatory operations team is notified of the final version as soon as it is approved, and the format is standardized and PDF validation is performed. This incremental dossier lock method is a practical way to distribute excessive workloads that are concentrated at the last minute and improve the completeness of the documents. By performing constant pre-validation, broken links or incorrectly entered metadata errors can be corrected early, preventing urgent corrections that may occur at the time of final submission.

Maximizing Corporate Value and the Market Outlook for Regulatory Operations Software

Successful new drug development culminates in timely submission and rapid commercialization through shortened regulatory agency review times. The global Regulatory Information Management (RIM) market is expected to grow from $2.7 billion in 2026 to $7.6 billion in 2036, with an annual growth rate of approximately 11%, making it a promising technology sector. This can be interpreted as a clear sign that global pharmaceutical companies are strengthening their investments in regulatory technology (RegTech) to enhance the value of new drugs. From an investor's perspective, when evaluating a pharmaceutical company's pipeline, it is necessary to assess not only Phase 3 data but also the maturity of regulatory operations that can lead to approval.